Envudeucitinib Phase 3 Results Highlight Alumis’ Progress—Robust PASI 90/100 Outcomes and Strong Cash Position Underline Growth Potential
Market Chameleon (Fri, 15-May 10:38 AM)
Alumis Delivers Positive Phase 3 Results for Envudeucitinib—Cash Position Strengthens Outlook Into 2027
Market Chameleon (Fri, 20-Mar 10:22 AM)
